Xuefei Zhou

TL;DR: This review analyzes the cancer gene‐delivery cascade and the barriers, the needed nanopro properties and the current strategies for overcoming these barriers, and outlines PEGylation, surface‐charge, size, and stability dilemmas in vector nanoproperties to efficiently accomplish the cancer genes delivery cascade.

TL;DR: In colorectal, pancreatic, and breast cancer liver metastasis models, the RLN gene therapy results in significant inhibition of metastatic progression and prolongs survival and the combination of the RLNs gene therapy with PD-L1 blockade immunotherapy produces a synergistic anti-metastatic efficacy.

TL;DR: A novel strategy combining chemotherapy and immunotherapy to modulate the TME by systemically and concurrently delivering the chemotherapeutic agent SN38 and the STING agonist DMXAA into tumors shows potent therapeutic efficacy in three mice tumor models and elicits remarkable therapeutic benefit when combined with anti–PD-1 therapy.

TL;DR: Intervention of macrophage phagocytosis by blocking anti‐phagocytic signals on live tumor cells or inhibiting tumor efferocyTosis presents a promising strategy for the development of cancer immunotherapies.

TL;DR: It is shown that celastrol (CEL) induced not only strong ICD but also downregulation of PD-L1 expression of tumor cells, demonstrating a new and much cost-effective immunotherapy strategy - chemotherapy-induced immunotherapy against melanoma without the need for expensive immune-checkpoint inhibitors.